Tenosynovial Giant Cell Tumor (TGCT) Real-World Participant Experience With Vimseltinib
Real-World Patient Experience of Vimseltinib for the Treatment of Tenosynovial Giant Cell Tumor
Deciphera Pharmaceuticals, LLC
100 participants
Sep 3, 2025
OBSERVATIONAL
Conditions
Summary
The goal of this observational study is to better understand real-world use of vimseltinib, treatment patterns, and health-related quality of life in participants treated with vimseltinib for TGCT. This study will collect data in an observational disease registry involving no intervention to the participants and will not influence standard medical care or impact treatment decisions for participants.
Eligibility
Inclusion Criteria3
- Diagnosis of TGCT according to medical records
- Prescribed vimseltinib per the approved label requirements. Participants are eligible if either (A) the decision to receive vimseltinib has been made but treatment has not yet been initiated or (B) the decision to receive vimseltinib has been made and participant has received first dose of prescribed vimseltinib less than 6 months prior to study enrollment
- Has provided informed consent and medical records release
Exclusion Criteria3
- Participant has received any other systemic agent for the treatment of TGCT during the 6 months prior to starting treatment with vimseltinib
- Participant has received the first dose of prescribed vimseltinib in the current treatment course more than 6 months before study enrollment
- Participant is active in an interventional clinical trial of vimseltinib
Interested in this trial?
Get notified about updates and connect with the research team.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07075471